% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kruse:280979,
      author       = {Kruse, Sebastian and Fricke, Lia T. and Zottnick, Samantha
                      and Schlosser, Ann-Katrin and Grabowska, Agnieszka K. and
                      Feidt, Eva and Uhl, Philipp and Junglas, Ellen and Förster,
                      Jonas D. and Blersch, Josephine and Denner, Philip and
                      Günter, Manina and Autenrieth, Stella E. and Fava, Eugenio
                      and Mier, Walter and Kübelbeck, Armin and Riemer, Angelika
                      B.},
      title        = {{A} versatile silica nanoparticle platform for induction of
                      {T} cell responses – applied for therapeutic vaccination
                      against {HPV}16 {E}6/{E}7-positive tumors in {MHC}-humanized
                      mice},
      journal      = {OncoImmunology},
      volume       = {14},
      number       = {1},
      issn         = {2162-4011},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Franics},
      reportid     = {DZNE-2025-01061},
      pages        = {2548002},
      year         = {2025},
      abstract     = {Therapeutic vaccines represent a promising treatment option
                      for (pre)cancerous lesions, such as human
                      papillomavirus-induced malignancies. They act via
                      administration of tumor-specific antigens, leading to
                      induction of antigen-specific cytotoxic T cell responses.
                      However, vaccination efficiency is often limited when the
                      antigen is administered alone, due to antigen instability
                      and inefficient uptake by antigen-presenting cells (APCs).
                      To address these limitations, nanoparticle-based vaccine
                      delivery systems are currently under investigation. Here, we
                      present a novel silica nanoparticle (SiNP)-based vaccine
                      delivery platform that can be applied for the treatment of
                      various diseases and cancer types. We show that
                      surface-functionalized SiNPs are non-cytotoxic and quickly
                      taken up by APCs. Incorporation of a linker/solubilizer
                      sequence N-terminal of the epitope allows attachment of
                      peptides regardless of their solubility as well as efficient
                      processing and surface presentation by APCs. Whole-body
                      distribution studies confirmed retention of the antigen at
                      the injection site and decelerated excretion when connected
                      to SiNPs. Furthermore, treatment with SiNPs, especially when
                      combined with the adjuvant poly(I:C), resulted in activation
                      of dendritic cells capable of priming CD8+ T cells. In
                      C57BL/6 and MHC-humanized A2.DR1 mice, the SiNP-based
                      vaccinations induced epitope-specific CD8+ T cells.
                      Moreover, they exhibited anti-tumor activity and provided a
                      survival benefit in a tumor model using HPV16
                      E6/E7-expressing PAP-A2 cells. Thus, the novel SiNP platform
                      represents a promising new vehicle for therapeutic vaccine
                      delivery.},
      cin          = {CRFS / LAT},
      ddc          = {610},
      cid          = {I:(DE-2719)1040000 / I:(DE-2719)1040190},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40981650},
      doi          = {10.1080/2162402X.2025.2548002},
      url          = {https://pub.dzne.de/record/280979},
}